|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Moexipril#Overdosage]] |
| {{Moexipril}}
| |
| {{CMG}}; {{AE}} {{AM}}
| |
| | |
| ==Overdosage==
| |
| | |
| Human overdoses of moexipril have not been reported. In case reports of overdoses with other ACE inhibitors, [[hypotension]] has been the principal adverse effect noted. Single oral doses of 2 g/kg moexipril were associated with significant lethality in mice. Rats, however, tolerated single oral doses of up to 3 g/kg.
| |
| | |
| No data are available to suggest that physiological maneuvers (e.g., maneuvers to change the pH of the urine) would accelerate elimination of moexipril and its metabolites. The dialyzability of moexipril is not known.
| |
| | |
| [[Angiotensin II]] could presumably serve as a specific antagonist-antidote in the setting of moexipril overdose, but angiotensin II is essentially unavailable outside of research facilities. Because the hypotensive effect of moexipril is achieved through vasodilation and effective hypovolemia, it is reasonable to treat moexipril overdose by infusion of normal saline solution. In addition, renal function and serum potassium should be monitored.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MOEXIPRIL HYDROCHLORIDE TABLET [APOTEX CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d18108f5-98ca-1220-d145-bcf4e71ceaee | publisher = | date = | accessdate = }}</ref>
| |
| | |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |